[8-K] ProKidney Corp. Reports Material Event

Rhea-AI Filing Summary

ProKidney Corp. (Nasdaq: PROK) furnished a Current Report on Form 8-K stating that it issued a press release announcing its financial results for the quarter ended June 30, 2025. The press release is furnished as Exhibit 99.1, and the filing also references an Inline XBRL cover page file for the report.

The report notes that the furnished press release and related information are not being "filed" for purposes of certain Exchange Act liabilities and will not be incorporated by reference into other registration statements unless expressly stated. The filing identifies ProKidney as an emerging growth company and is signed on behalf of the registrant by Chief Financial Officer James Coulston.

Insights

Financial Analyst

TL;DR: The company furnished its Q2 2025 earnings press release but provided no financial figures in the 8-K, so impact cannot be assessed here.

The Current Report on Form 8-K discloses that ProKidney issued a press release reporting results for the quarter ended June 30, 2025 and furnished it as Exhibit 99.1. The filing explicitly states the furnished material is not to be treated as "filed" under the Exchange Act, which is standard practice when companies provide press releases. Because the 8-K does not reproduce the press release text or include financial statements or metrics, this filing alone does not provide the data required to evaluate revenue, profitability, cash position, or changes versus prior periods. Investors must review Exhibit 99.1 or other filings for substantive numbers.

Corporate Governance Expert

TL;DR: Routine disclosure process observed; emergence as an "emerging growth company" is affirmed and exhibits are properly identified.

ProKidney indicates it is an emerging growth company, checked on the form, and the 8-K lists Exhibit 99.1 (press release) and Inline XBRL cover page as attachments. The filing follows typical disclosure conventions by furnishing rather than filing the press release and by having an authorized officer, CFO James Coulston, sign the report. The document contains no governance changes, officer departures, or other corporate-action disclosures.

false000185027000018502702025-08-122025-08-12

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 12, 2025

PROKIDNEY CORP.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-40560	98-1586514
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
2000 Frontis Plaza Blvd. Suite 250
Winston-Salem, North Carolina				27103
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 336 999-7019

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Class A common stock, $0.0001 par value per share		PROK		The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 12, 2025, ProKidney Corp. (the "Company") issued a press release to announce its financial results for the quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1.

The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section, and shall not be deemed to be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Press Release dated August 12, 2025
104	Cover Page Interactive Data File (embedded within Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			PROKIDNEY CORP.
Date:	August 12, 2025	By:	/s/ James Coulston
			James Coulston Chief Financial Officer

FAQ

What did ProKidney (PROK) report in this 8-K?

The 8-K states ProKidney furnished a press release announcing financial results for the quarter ended June 30, 2025, provided as Exhibit 99.1.

Is ProKidney listed on an exchange and what is its ticker?

Yes. The filing shows the company’s Class A common stock trades on The Nasdaq Stock Market under the ticker PROK.

Does the 8-K include the financial results themselves?

No. The Form 8-K notes the press release was furnished as an exhibit but the filing text does not contain specific financial figures or statements.

Is ProKidney an emerging growth company?

Yes. The form indicates the registrant checked the box marking it as an emerging growth company.

What exhibits are attached to the 8-K?

The 8-K lists Exhibit 99.1 (Press Release dated August 12, 2025) and Exhibit 104 (Cover Page Interactive Data File embedded in Inline XBRL).

Who signed the 8-K on behalf of ProKidney?

The report is signed on behalf of the registrant by James Coulston, Chief Financial Officer.